Please assess the completion status of the following clinical trial:

Trial Title: Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Community-living men and women age 65 and older~* Age-related cognitive decline as defined by (a) self-reported cognitive dysfunction that is attributed to the aging process (in response to screening questions to the participant); (b) ability to complete cognitive battery, but still scoring less than 1 standard deviation above age-matched norms at both baseline and after the two-week cognitive training lead-in.~Exclusion Criteria:~* Known dementia or other clinical neurodegenerative illness (e.g., Parkinson's disease, cerebrovascular disease) per self-report, informant report, medical records, or neuropsychological testing~* Any current psychiatric disorder~* Medical conditions that suggest shortened lifespan, such as metastatic cancer; or would prohibit safe participation in the interventions, including cardiovascular disease or musculoskeletal conditions; or with the assessments.~* Sensory impairment that would prevent participation~* IQ \< 70 as estimated by the Wechsler Test of Adult Reading~* Alcohol or substance abuse within 6 months~* Concurrent cognitive training, such as brain-training software, or other interventions expected to affect neuroplasticity~* Psychotropic medications or those with likely CNS effects (none within 4 weeks prior to study entry)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vortioxetine plus cognitive training (Type: EXPERIMENTAL): Vortioxetine (10 mg) plus cognitive training 5 times weekly for 30 minutes a day
- Placebo plus cognitive training (Type: PLACEBO_COMPARATOR): Placebo plus cognitive training 5 times weekly for 30 minutes a day

Based on this trial design, predict the completion outcome and termination type (if applicable).